Hologic (NASDAQ:HOLX) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Hologic (NASDAQ:HOLX - Free Report) in a report published on Tuesday, MarketBeat Ratings reports. The brokerage issued a hold rating and a $85.00 price objective on the medical equipment provider's stock.

Several other equities research analysts have also recently commented on the company. Needham & Company LLC reissued a "buy" rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, October 15th. Leerink Partners decreased their target price on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. StockNews.com upgraded shares of Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. UBS Group increased their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Finally, Raymond James boosted their price target on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Hologic has a consensus rating of "Moderate Buy" and a consensus price target of $89.50.

Hologic Stock Up 1.4 %

HOLX stock traded up $1.04 during midday trading on Tuesday, reaching $76.83. The company had a trading volume of 3,905,240 shares, compared to its average volume of 1,607,660. The company has a 50 day moving average of $79.69 and a two-hundred day moving average of $78.58. The company has a market capitalization of $17.44 billion, a P/E ratio of 23.16, a PEG ratio of 2.37 and a beta of 0.96. Hologic has a 1 year low of $68.15 and a 1 year high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period last year, the company earned $0.89 earnings per share. Hologic's quarterly revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.75% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Innealta Capital LLC acquired a new stake in shares of Hologic in the 2nd quarter valued at $25,000. Wolff Wiese Magana LLC bought a new position in Hologic during the 3rd quarter valued at about $25,000. Groupama Asset Managment boosted its position in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 2,999 shares in the last quarter. Sunbelt Securities Inc. bought a new stake in Hologic during the second quarter worth about $37,000. Finally, First Horizon Advisors Inc. increased its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.